News for Sangamo Therapeutics, Inc. (0R1D.L)

On May 14, 2025, Barclays analyst Gena Wang announced an update regarding their stance on Sangamo Therapeutics (SGMO). The firm has maintained its "Overweight"

Upfront License Fee: Received $18 million from Eli Lilly for the first target under the STAC-BBB license agreement.Potential Milestone Payments: Eligible to ea

Key Highlights: Sangamo Therapeutics embarks on a substantial $23 million capital raise. Analysts foresee a significant upside potential for SGMO stock.

U.S. stock futures fell on Tuesday after a stellar rally on Monday. Futures of major benchmark indices were trading lower in premarket.

Shares of Coinbase Global, Inc. COIN rose sharply in today's pre-market trading. Coinbase is set to join the S&P 500, replacing Discover Financial Services DFS...

Release Date: May 12, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Sangamo Therapeut

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NSGMO.OQ - Sangamo Therapeutics IncQ1 2025 Sangamo Therapeutics Inc Earnings CallMay 12, 2025 /

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 12,235,000 shares

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and first quarter 2025 financial results. ”œ

Sangamo Therapeutics (SGMO) has outlined its financial expectations for 2025. On a Generally Accepted Accounting Principles (GAAP) basis, the company anticipate

The following slide deck was published by Sangamo Therapeutics, Inc.

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the first quarter earnings call originally scheduled for 4:30p.m. E

Sangamo Therapeutics, Inc.'s $18M Eli Lilly deal boosts CNS genomic medicines. Fabry gene therapy data in 2025 is key for investors. Click for my SGMO stock update.

U.S. stock futures continued to decline on Friday after a bloodbath on Thursday following the introduction of Donald Trump's tariffs.

U.S. stock futures continued to decline on Friday after a bloodbath on Thursday following the introduction of Donald Trump's tariffs.

Shares of Sangamo Therapeutics, Inc. SGMO rose sharply in today's pre-market trading after the company announced a new agreement with pharmaceutical giant Eli L...

With U.S. stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows: Wall Street expects America...

The stock market experienced a significant downturn today, with the S&P 500 dropping nearly 5% to 5,396.52, marking its worst session since September 2022.

Key Highlights: Sangamo Therapeutics (SGMO) secures an exclusive licensing agreement with Eli Lilly. Potential deal value reaches up to $1.4 billion, sta